Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
Phase III trials of the anti-insulin-like growth factor-1 receptor (IGF1R) antibody figitumumab in non-small cell lung cancer (NSCLC) patients have been discontinued owing to lack of survival benefit. We investigated whether inhibition of the highly homologous insulin receptor (IR) in addition to th...
Main Authors: | Emma E Vincent, Douglas J E Elder, Jon Curwen, Elaine Kilgour, Ingeborg Hers, Jeremy M Tavaré |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3691253?pdf=render |
Similar Items
-
The insulin receptor and insulin stimulated protein kinase : Their role in insulin action
by: Tavare, J. M.
Published: (1985) -
Bariatric surgery in morbidly obese insulin resistant humans normalises insulin signalling but not insulin-stimulated glucose disposal.
by: Mimi Z Chen, et al.
Published: (2015-01-01) -
Ligand-mediated Endocytosis and Trafficking of the Insulin-like Growth Factor Receptor I and Insulin Receptor Modulate Receptor Function
by: Alaide eMorcavallo, et al.
Published: (2014-12-01) -
Differential Roles of Insulin-like Growth Factor Receptor- and Insulin Receptor-mediated Signaling in the Phenotypes of Hepatocellular Carcinoma Cells
by: Ya-Wen Chen, et al.
Published: (2009-09-01) -
EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTORS ON SATELLITE CELL PROLIFERATION IN VITRO (SOMATOMEDINS, RECEPTORS).
by: Dodson, Michael Verne
Published: (1985)